Parham Academy LLC
European Academy of Biomedical Sciences

Our news & hot issues

ISI Impact factor= 5.49 (Q1)

Each weekend, you are linked to the best article that , during each week, I have read and found it great in the field of Cancer and Pharmacology. I try to encourage the fellow researchers and post-graduate students to read so much as they can about new therapeutics.

Weekend Recipe for January 2016 - the first week

Antibody Drug Conjugates for Cancer Therapy

Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody. The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell. Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clinical evaluation. This review primarily covers ADCs that have advanced to clinical investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.

Download this recipe

To download other weekend recipes click here.

Author watson Home 13:34:12 | | | printer friendly | | create pdf of this news item

Our article: Therapeutic miRNAs

 Pharmacological Research


Date published: not known

»Measuring the far side of the Galaxy
»3D gene expression blueprint of the fly
»Mechanical systems at the quantum level
»3D texture morphing for camouflage
»A signature event for organoids
»Forests out of balance
»Fevers, TRPV channels, and birth defects
»Newborn brain imaging made easier
»Light- and dark-zone death dynamics
»A radical route from methane to methanol

Date published: not known

»Correction to "A Scale of Agonism and Allosteric Modulation for Assessment of Selectivity, Bias, and Receptor Mutation" [ERRATUM]
»E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis [Articles]
The chemokine fractalkine (CX3C chemokine ligand 1; CX3CL1) and its receptor CX3CR1 are involved in ...
»Selective HIF-1 Regulation under Nonhypoxic Conditions by the p42/p44 MAP Kinase Inhibitor PD184161 [Articles]
Hypoxia-inducible factor-1 (HIF-1) is a key gene regulator for cellular adaptation to low oxygen. I ...
»Transforming Growth Factor-{beta}1/Activin Receptor-like Kinase 5-Mediated Cell Migration is Dependent on the Protein Proteinase-Activated Receptor 2 but not on Proteinase-Activated Receptor 2-Stimulated Gq-Calcium Signaling [Articles]
Transforming growth factor-β (TGF-β), serine proteinases such as trypsin, and proteinase- ...
»Prostaglandin E2 Inhibits Histamine-Evoked Ca2+ Release in Human Aortic Smooth Muscle Cells through Hyperactive cAMP Signaling Junctions and Protein Kinase A [Articles]
In human aortic smooth muscle cells, prostaglandin E2 (PGE2) stimulates adenylyl cyclase (AC) and a ...
»A Single Amino Acid Substitution in the Third Transmembrane Region Has Opposite Impacts on the Selectivity of the Parasiticides Fluralaner and Ivermectin for Ligand-Gated Chloride Channels [Articles]
Fluralaner (Bravecto) is a recently marketed isoxazoline ectoparasiticide. This compound potently i ...
»The Actions of Drug Combinations on the GABAA Receptor Manifest as Curvilinear Isoboles of Additivity [Accelerated Communication]
Drug interactions are often analyzed in terms of isobolograms. In the isobologram, the line connect ...
»N-Acetyl-L-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to Glutathione [Articles]
N-acetyl-l-cysteine (NAC) exhibits protective properties in brain injury models and has undergone a ...
»The Anthracycline Metabolite Doxorubicinol Abolishes RyR2 Sensitivity to Physiological Changes in Luminal Ca2+ through an Interaction with Calsequestrin [Articles]
The chemotherapeutic anthracycline metabolite doxorubicinol (doxOL) has been shown to interact with ...
»Agonist-Dependent and -Independent {kappa} Opioid Receptor Phosphorylation: Distinct Phosphorylation Patterns and Different Cellular Outcomes [Articles]
We reported previously that the selective agonist U50,488H promoted phosphorylation of the mouse o ...

Date published: not known

»A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action
»Clusternomics: Integrative context-dependent clustering for heterogeneous datasets
»The role of glutamate in neuronal ion homeostasis: A case study of spreading depolarization
»Network approaches and applications in biology
»Ten simple rules for writing a response to reviewers
»BeWith: A Between-Within method to discover relationships between cancer modules via integrated analysis of mutual exclusivity, co-occurrence and functional interactions
»Identifying direct contacts between protein complex subunits from their conditional dependence in proteomics datasets
»Vicus: Exploiting local structures to improve network-based analysis of biological data
»Systematic, network-based characterization of therapeutic target inhibitors
»Network propagation in the cytoscape cyberinfrastructure
»Incorporating networks in a probabilistic graphical model to find drivers for complex human diseases
»Structural host-microbiota interaction networks

Date published: not known


Parham Jabbarzadeh Kaboli, PhD

Research scientist
in molecular medicine

Expert in:

Cell and molecular Biology
Modelling and drug discovery
Cancer signaling pathways

H-index= 3 (Google Scholar)
i10-index= 3
Overall ISI impact factor= 18.15
Overall citation= 110 (Google Scholar)


The American Society for Pharmacology and Experimental Therapeutics (ASPET)

American Association for Cancer Research (AACR)

European Association for Cancer Research (EACR)

American Association for Advancement of Science (AAAS)


Department of Biomedical Science,
Faculty of Medicine and Health Sciences,
Universiti Putra Malaysia,
UPM Serdang 43400,
Selangor, Malaysia

Featured Publication

View the full list.




[ ]

This site is powered by Parham Academy.
This site is powered by Parham Academy.
Render time: 0.1260 sec, 0.0065 of that for queries.